All Title Author
Keywords Abstract

Recurrent Focal Segmental Glomerulosclerosis: A Discrete Clinical Entity

DOI: 10.1155/2012/246128

Full-Text   Cite this paper   Add to My Lib


Focal segmental glomerulosclerosis refers to a set of particular histopathologic lesions in which steroid-resistant podocyte injury leads to patchy adhesions between the glomerular tuft and Bowman's capsule, followed by progressive glomerulosclerosis and proteinuric renal failure. Because of the nonspecific nature of this lesion, it has been difficult to classify the various forms of primary nephrotic syndrome in children. However, with the recognition of hereditary FSGS caused by mutations podocyte slit diaphragm genes, it is increasingly clear that the steroid-resistant form of FSGS that recurs in the renal allografts (R-FSGS) constitutes a distinct clinical entity. Capitalizing on recent studies in which patients have been screened for slit diaphragm gene mutations, this review focuses on the natural history and pathogenesis of R-FSGS. 1. R-FSGS in the Context of Steroid-Resistant Nephrotic Syndrome A recent population-based study in the Gironde region of France reported an incidence of about 2.3 pediatric cases of idiopathic nephrotic syndrome for every 100,000 children <15 years of age [1]. The majority (91%) of these children exhibited a classical steroid-responsive relapsing disease, in which there may be podocyte foot process effacement noted on renal biopsy but no progressive renal insufficiency. Estimates of steroid-responsiveness are somewhat lower (80%) in referral populations or cohorts that include adults [2]. Among those who fail to respond to daily steroid therapy for 4 weeks, renal biopsies usually reveal a progressive lesion in which early podocyte detachment from the glomerular basement membrane is associated with segmental hyalinosis of the glomerular capillary tuft and, eventually, fibrotic adhesions to Bowman's capsule. It is the patchy distribution of these lesions within the glomerulus and the initial sparing of some glomeruli that warrant the pathologic descriptor, focal segmental glomerulosclerosis (FSGS). In New York City, about two thirds of steroid-resistant nephrotic syndrome (SRNS) patients display FSGS on renal biopsy [3]. In the setting of SRNS, these lesions are associated with high risk of progressive renal failure [4]. Collectively, these children comprise nearly 15% of the dialysis and renal transplant population in North America. However, the FSGS lesion is not pathognomonic for a specific clinical entity but rather reflects any process that leads to patchy irreversible podocyte injury. In addition to the many disorders that cause “secondary” glomerulosclerosis, children with steroid-sensitive nephrotic syndrome


[1]  S. Ernould, A. Godron, J. -R. Nelson, C. Rigothier, B. Llanas, and J. Harambat, “Idiopathic nephrotic syndrome in children: incidence, clinical presentation, and outcome in the county of Gironde, France,” Archives de Pediatrie, vol. 18, no. 5, pp. 522–528, 2011.
[2]  R. Gbadegesin, B. Hinkes, C. Vlangos et al., “Mutational analysis of NPHS2 and WT1 in frequently relapsing and steroid-dependent nephrotic syndrome,” Pediatric Nephrology, vol. 22, no. 4, pp. 509–513, 2007.
[3]  A. Tejani, K. Phadke, and A. Nicastri, “Efficacy of cyclophosphamide in steroid-sensitive childhood nephrotic syndrome with different morphological lesions,” Nephron, vol. 41, no. 2, pp. 170–173, 1985.
[4]  J. Churg and J. L. Duffy, “Classification of glomerulonephritis based on morphology,” Perspectives in Nephrology and Hypertension, vol. 1, pp. 43–61, 1973.
[5]  A. Tejani, “Morphological transition in minimal change nephrotic syndrome,” Nephron, vol. 39, no. 3, pp. 157–159, 1985.
[6]  F. Fakhouri, N. Bocquet, P. Taupin et al., “Steroid-sensitive nephrotic syndrome: from childhood to adulthood,” American Journal of Kidney Diseases, vol. 41, no. 3, pp. 550–557, 2003.
[7]  P. Schwaderer, T. Knüppel, M. Konrad et al., “Clinical course and NPHS2 analysis in patients with late steroid-resistant nephrotic syndrome,” Pediatric Nephrology, vol. 23, no. 2, pp. 251–256, 2008.
[8]  H. A. C. Kyrieleis, M. M. L?wik, I. Pronk et al., “Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 10, pp. 1593–1600, 2009.
[9]  V. Sümegi, I. Haszon, C. Bereczki, F. Papp, and S. Túri, “Long-term follow-up after cyclophosphamide and cyclosporine-A therapy in steroid-dependent and -resistant nephrotic syndrome,” Pediatric Nephrology, vol. 23, no. 7, pp. 1085–1092, 2008.
[10]  M. B. Stadermann, M. R. Lilien, N. C. A. J. van de Kar, L. A. H. Monnens, and C. H. Schr?der, “Is biopsy required prior to cyclophosphamide in steroid-sensitive nephrotic syndrome?” Clinical Nephrology, vol. 60, no. 5, pp. 315–317, 2003.
[11]  P. Niaudet, “Lipoid nephrosis in childhood,” Revue du Praticien, vol. 53, no. 18, pp. 2027–2032, 2003.
[12]  A. R. RICH, “A hitherto undescribed vulnerability of the juxtamedullary glomeruli in lipoid nephrosis,” Bulletin of the Johns Hopkins Hospital, vol. 100, no. 4, pp. 173–186, 1957.
[13]  J. R. Hoyer, R. L. Vernier, J. S. Najarian, L. Raij, R. L. Simmons, and A. F. Michael, “Recurrence of idiopathic nephrotic syndrome after renal transplantation,” Lancet, vol. 2, no. 7773, pp. 343–348, 1972.
[14]  T. C. Jungraithmayr, K. Hofer, P. Cochat et al., “Screening for NPHS2 mutations may help predict FSGS recurrence after transplantation,” Journal of the American Society of Nephrology, vol. 22, no. 3, pp. 579–585, 2011.
[15]  E. J. B. Monteiro, A. C. Pereira, A. B. Pereira, J. E. Krieger, and G. Mastroianni-Kirsztajn, “NPHS2 mutations in adult patients with primary focal segmental glomerulosclerosis,” Journal of Nephrology, vol. 19, no. 3, pp. 366–371, 2006.
[16]  N. He, A. Zahirieh, Y. Mei et al., “Recessive NPHS2 (Podocin) mutations are rare in adult-onset idiopathic focal segmental glomerulosclerosis,” Clinical Journal of the American Society of Nephrology, vol. 2, no. 1, pp. 31–37, 2007.
[17]  G. Canaud, D. Dion, J. Zuber et al., “Recurrence of nephrotic syndrome after transplantation in a mixed population of children and adults: course of glomerular lesions and value of the Columbia classification of histological variants of focal and segmental glomerulosclerosis (FSGS),” Nephrology Dialysis Transplantation, vol. 25, no. 4, pp. 1321–1328, 2010.
[18]  V. D. D'Agati, A. B. Fogo, J. A. Bruijn, and J. C. Jennette, “Pathologic classification of focal segmental glomerulosclerosis: a working proposal,” American Journal of Kidney Diseases, vol. 43, no. 2, pp. 368–382, 2004.
[19]  D. H. T. Ijpelaar, A. B. Farris, N. Goemaere et al., “Fidelity and evolution of recurrent FSGS in renal allografts,” Journal of the American Society of Nephrology, vol. 19, no. 11, pp. 2219–2224, 2008.
[20]  R. J. M. Coward, R. R. Foster, D. Patton et al., “Nephrotic plasma alters slit diaphragm-dependent signaling and translocates nephrin, podocin, and CD2 associated protein in cultured human podocytes,” Journal of the American Society of Nephrology, vol. 16, no. 3, pp. 629–637, 2005.
[21]  R. Sharma, M. Sharma, E. T. McCarthy, X. L. Ge, and V. J. Savin, “Components of normal serum block the focal segmental glomerulosclerosis factor activity in vitro,” Kidney International, vol. 58, no. 5, pp. 1973–1979, 2000.
[22]  G. Canaud, J. Zuber, R. Sberro et al., “Intensive and prolonged treatment of focal and segmental glomerulosclerosis recurrence in adult kidney transplant recipients: a pilot study,” American Journal of Transplantation, vol. 9, no. 5, pp. 1081–1086, 2009.
[23]  G. Lagrue, A. Branellec, P. Niaudet, J. M. Heslan, F. Guillot, and P. Lang, “Transmission of nephrotic syndrome to two neonates. Spontaneous regression,” Presse Medicale, vol. 20, no. 6, pp. 255–257, 1991.
[24]  S. V. Orman, G. P. Schechter, and J. Whang-Peng, “Nephrotic syndrome associated with a clonal T-cell leukemia of large granular lymphocytes with cytotoxic function,” Archives of Internal Medicine, vol. 146, no. 9, pp. 1827–1829, 1986.
[25]  L. Le Berre, S. Bruneau, J. Naulet et al., “Induction of T regulatory cells attenuates idiopathic nephrotic syndrome,” Journal of the American Society of Nephrology, vol. 20, no. 1, pp. 57–67, 2009.
[26]  L. Bao, O. Brad Spiller, P. L. St. John P.L. et al., “Decay-accelerating factor expression in the rat kidney is restricted to the apical surface of podocytes,” Kidney International, vol. 62, no. 6, pp. 2010–2021, 2002.
[27]  K. Benz, J. D?tsch, W. Rascher, and D. Stachel, “Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy,” Pediatric Nephrology, vol. 19, no. 7, pp. 794–797, 2004.
[28]  R. D. Gilbert, E. Hulse, and S. Rigden, “Rituximab therapy for steroid-dependent minimal change nephrotic syndrome,” Pediatric Nephrology, vol. 21, no. 11, pp. 1698–1700, 2006.
[29]  M. D. Pescovitz, B. K. Book, and R. A. Sidner, “Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment,” New England Journal of Medicine, vol. 354, no. 18, pp. 1961–1963, 2006.
[30]  A. Bagga, A. Sinha, and A. Moudgil, “Rituximab in patients with the steroid-resistant nephrotic syndrome,” New England Journal of Medicine, vol. 356, no. 26, pp. 2751–2752, 2007.
[31]  E. T. McCarthy, M. Sharma, R. Sharma, R. J. Falk, and J. C. Jennette, “Sera from patients with collapsing focal segmental glomerulosclerosis increase albumin permeability of isolated glomeruli,” Journal of Laboratory and Clinical Medicine, vol. 143, no. 4, pp. 225–229, 2004.
[32]  V. J. Savin, E. T. McCarthy, R. Sharma, D. Charba, and M. Sharma, “Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity,” Translational Research, vol. 151, no. 6, pp. 288–292, 2008.
[33]  C. Wei, S. El Hindi, J. Li et al., “Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis,” Nature Medicine, vol. 17, no. 8, pp. 952–960, 2011.
[34]  K. Bifulco, M. V. Carriero, I. Longanesi-Cattani et al., “Involvement of the soluble urokinase receptor in chondrosarcoma cell mobilization,” Sarcoma, vol. 2011, Article ID 842842, 10 pages, 2011.
[35]  S. Leroy, V. Guigonis, D. Bruckner et al., “Successful anti-TNFα treatment in a child with posttransplant recurrent focal segmental glomerulosclerosis,” American Journal of Transplantation, vol. 9, no. 4, pp. 858–861, 2009.
[36]  A. Bakr, M. Shokeir, F. El-Chenawi, F. El-Husseni, A. Abdel-Rahman, and R. El-Ashry, “Tumor necrosis factor-α production from mononuclear cells in nephrotic syndrome,” Pediatric Nephrology, vol. 18, no. 6, pp. 516–520, 2003.
[37]  F. Assadi, “Neonatal nephrotic syndrome associated with placental transmission of proinflammatory cytokines,” Pediatric Nephrology, vol. 26, no. 3, pp. 1–3, 2010.
[38]  L. A. Bruggeman, P. E. Drawz, N. Kahoud, K. Lin, L. Barisoni, and P. J. Nelson, “TNFR2 interposes the proliferative and NF-B-mediated inflammatory response by podocytes to TNF-α,” Laboratory Investigation, vol. 91, no. 3, pp. 413–425, 2011.
[39]  S. Doublier, L. Musante, E. Lupia et al., “Direct effect of plasma permeability factors from patients with idiopatic FSGS on nephrin and podocin expression in human podocytes,” International Journal of Molecular Medicine, vol. 16, no. 1, pp. 49–58, 2005.
[40]  S. Babayeva, Y. Zilber, and E. Torban, “Planar cell polarity pathway regulates actin rearrangement, cell shape, motility, and nephrin distribution in podocytes,” American Journal of Physiology. Renal Physiology, vol. 300, no. 2, pp. F549–F560, 2011.
[41]  S. Babayeva, M. Miller, Y. Zilber et al., “Plasma from a case of recurrent idiopathic FSGS perturbs non-muscle myosin IIA (MYH9 protein) in human podocytes,” Pediatric Nephrology, vol. 26, no. 7, pp. 1071–1081, 2011.
[42]  L. H. No?l, “Morphological features of primary focal and segmental glomerulosclerosis,” Nephrology Dialysis Transplantation, vol. 14, supplement 3, pp. 53–57, 1999.
[43]  T. Nakamura, C. Ushiyama, S. Suzuki et al., “The urinary podocyte as a marker for the differential diagnosis of idiopathic focal glomerulosclerosis and minimal-change nephrotic syndrome,” American Journal of Nephrology, vol. 20, no. 3, pp. 175–179, 2000.
[44]  C. A. Chen, J. C. Hwang, J. Y. Guh, J. M. Chang, Y. H. Lai, and H. C. Chen, “Reduced podocyte expression of α3β1 integrins and podocyte depletion in patients with primary focal segmental glomerulosclerosis and chronic PAN-treated rats,” Journal of Laboratory and Clinical Medicine, vol. 147, no. 2, pp. 74–82, 2006.
[45]  W. Kriz, H. Hosser, B. H?hnel, N. Gretz, and A. P. Provoost, “From segmental glomerulosclerosis to total nephron degeneration and interstitial fibrosis: a histopathological study in rat models and human gomerulopathies,” Nephrology Dialysis Transplantation, vol. 13, no. 11, pp. 2781–2798, 1998.
[46]  H. Dijkman, B. Smeets, J. Van Der Laak, E. Steenbergen, and J. Wetzels, “The parietal epithelial cell is crucially involved in human idiopathic focal segmental glomerulosclerosis,” Kidney International, vol. 68, no. 4, pp. 1562–1572, 2005.
[47]  J. Achenbach, M. Mengel, I. Tossidou et al., “Parietal epithelia cells in the urine as a marker of disease activity in glomerular diseases,” Nephrology Dialysis Transplantation, vol. 23, no. 10, pp. 3138–3145, 2008.
[48]  J. Bariéty, P. Bruneval, G. Hill, T. Irinopoulou, C. Mandet, and A. Meyrier, “Posttransplantation relapse of FSGS is characterized by glomerular epithelial cell transdifferentiation,” Journal of the American Society of Nephrology, vol. 12, no. 2, pp. 261–274, 2001.
[49]  B. Smeets, C. Kuppe, E. -M. Sicking et al., “Parietal epithelial cells participate in the formation of sclerotic lesions in focal segmental glomerulosclerosis,” Journal of the American Society of Nephrology, vol. 22, no. 7, pp. 1262–1274, 2011.
[50]  T. Ulinski, “Recurrence of focal segmental glomerulosclerosis after kidney transplantation: strategies and outcome,” Current Opinion in Organ Transplantation, vol. 15, no. 5, pp. 628–632, 2010.
[51]  M. Vinai, P. Waber, and M. G. Seikaly, “Recurrence of focal segmental glomerulosclerosis in renal allograft: an in-depth review,” Pediatric Transplantation, vol. 14, no. 3, pp. 314–325, 2010.
[52]  R. Salomon, M. F. Gagnadoux, and P. Niaudet, “Intravenous cyclosporine therapy in recurrent nephrotic syndrome after renal transplantation in children,” Transplantation, vol. 75, no. 6, pp. 810–814, 2003.
[53]  R. Dall'Amico, G. Ghiggeri, M. Carraro et al., “Prediction and treatment of recurrent focal segmental glomerulosclerosis after renal transplantation in children,” American Journal of Kidney Diseases, vol. 34, no. 6, pp. 1048–1055, 1999.
[54]  L. D. Strologo, I. Guzzo, C. Laurenzi et al., “Use of rituximab in focal glomerulosclerosis relapses after renal transplantation,” Transplantation, vol. 88, no. 3, pp. 417–420, 2009.
[55]  H. Kaito, K. Kamei, E. Kikuchi et al., “Successful treatment of collapsing focal segmental glomerulosclerosis with a combination of rituximab, steroids and ciclosporin,” Pediatric Nephrology, vol. 25, no. 5, pp. 957–959, 2010.
[56]  C. Sethna, et al., “Treatment of recurrent focal segmental glomerulosclerosis in pediatric kidney transplant recipients: effect of rituximab,” Journal of Transplantation, vol. 2011, Article ID 389542, 5 pages, 2011.
[57]  A. Fornoni, J. Sageshima, C. Wei et al., “Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis,” Science Translational Medicine, vol. 3, no. 85, Article ID 85ra46, 2011.


comments powered by Disqus

Contact Us


微信:OALib Journal